Los Angeles Capital Management
PTCT icon

Los Angeles Capital Management’s PTC Therapeutics PTCT Stock Holding History

Los Angeles Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56M Sell
55,926
-15,734
-22% -$1.14M 0.02% 439
2026
Q1 		$4.88M Buy
71,660
+39,239
+121% +$2.78M 0.02% 339
2025
Q4 		$2.21M Sell
32,421
-15,026
-32% -$1.09M 0.01% 425
2025
Q3 		$2.91M Buy
47,447
+1,538
+3% +$80.1K 0.01% 414
2025
Q2 		$2.24M Buy
45,909
+30,745
+203% +$1.46M 0.01% 434
2025
Q1 		$773K Buy
15,164
+34
+0.2% +$1.7K ﹤0.01% 635
2024
Q4 		$683K Hold
15,130
– – ﹤0.01% 729
2024
Q3 		$561K Buy
15,130
+4,325
+40% +$145K ﹤0.01% 830
2024
Q2 		$330K Buy
10,805
+5
+0% +$162 ﹤0.01% 982
2024
Q1 		$314K Buy
10,800
+2,024
+23% +$56.7K ﹤0.01% 986
2023
Q4 		$242K Buy
+8,776
New +$201K ﹤0.01% 1067
2023
Q3 		– Sell
-6,383
Closed -$260K – 1213
2023
Q2 		$260K Buy
6,383
+1,467
+30% +$71.8K ﹤0.01% 1049
2023
Q1 		$238K Buy
+4,916
New +$225K ﹤0.01% 1086
2021
Q2 		– Sell
-5,332
Closed -$252K – 1651
2021
Q1 		$252K Sell
5,332
-995
-16% -$59.1K ﹤0.01% 1479
2020
Q4 		$386K Sell
6,327
-9,608
-60% -$566K ﹤0.01% 1298
2020
Q3 		$745K Sell
15,935
-3,667
-19% -$181K ﹤0.01% 938
2020
Q2 		$995K Buy
19,602
+872
+5% +$42.8K ﹤0.01% 854
2020
Q1 		$836K Buy
18,730
+12,833
+218% +$646K 0.01% 758
2019
Q4 		$283K Buy
+5,897
New +$251K ﹤0.01% 1140
2019
Q3 		– Sell
-5,703
Closed -$257K – 1349
2019
Q2 		$257K Buy
+5,703
New +$225K ﹤0.01% 1230
2019
Q1 		– Sell
-8,823
Closed -$303K – 1418
2018
Q4 		$303K Sell
8,823
-670
-7% -$24.1K ﹤0.01% 1098
2018
Q3 		$446K Buy
+9,493
New +$393K ﹤0.01% 1129
2017
Q4 		– Sell
-11,460
Closed -$229K – 1373
2017
Q3 		$229K Buy
+11,460
New +$224K ﹤0.01% 1220

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Los Angeles Capital Management's PTCT Position: Q2 2026 in Review

Los Angeles Capital Management reduced its PTC Therapeutics (PTCT) stake by 22% in Q2 2026, selling an estimated $1.14M and leaving 55,926 shares worth $4.56M. The position accounts for 0.02% of the portfolio, ranked #439.

Los Angeles Capital Management first reported a position in PTCT in Q3 2017 and has held it in 23 quarters since. The position peaked at $4.88M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Los Angeles Capital Management held 55,926 shares of PTC Therapeutics worth $4.56M as of Q2 2026.
  • Los Angeles Capital Management sold 15,734 PTC Therapeutics shares in Q2 2026, an estimated $1.14M.
  • PTC Therapeutics made up 0.02% of Los Angeles Capital Management's portfolio in Q2 2026, its #439 holding.
  • Los Angeles Capital Management first reported a position in PTC Therapeutics in Q3 2017 and has held it in 23 quarters since.
  • Los Angeles Capital Management's PTC Therapeutics position peaked at $4.88M in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.